Impact of adjuvant chemotherapy delay on overall survival in early-stage breast cancer: a retrospective analysis
Systemic adjuvant chemotherapy given within < 2 months period since definitive surgery provides an optimal survival advantage. Notably, patients receiving late adjuvant chemotherapy > 6 months can still derive some benefit compared to those without treatment, making it a viable, though suboptimal, treatment option.
Authors
- Zeina Nahleh (ORCID: https://orcid.org/0000-0002-2489-1501)
- María Herrán
- Kaylee Sarna (ORCID: https://orcid.org/0000-0003-3533-111X)
- Rami Tfayli
- Theresa Abdo
- Ahmad Alhalabi (ORCID: https://orcid.org/0000-0002-7869-2153)
Institutions
- Cleveland Clinic Florida (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-09-19
- DOI
- https://doi.org/10.3389/fonc.2025.1666673
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Cleveland Clinic